MA-FORRESTER
5.2.2024 15:01:26 CET | Business Wire | Press release
Forrester (Nasdaq: FORR) today opened calls for nominations for its 2024 global Technology Awards in two categories: Technology Strategy Impact and Enterprise Architecture. These awards recognize organizations that align their technology strategies to their business goals, are quick to adapt to changing market conditions, and focus on building customer trust. Strong alignment is critical to business results: According to Forrester, firms with strong alignment grow 2.4 times faster than peers and have twice the profitability.
Nomination criteria for Forrester’s Technology Awards are as follows:
- Technology Strategy Impact. Award recipients must execute a high-performance IT strategy, which Forrester defines as the pursuit of continuous improvement of business results through technology. Recipients must also demonstrate how they use alignment, trust, and adaptivity to enhance business outcomes with their IT capabilities.
- Enterprise Architecture. This award, presented in partnership with The Open Group — author of the TOGAF® standard, developed by The Open Group Architecture Forum — recognizes organizations that demonstrate how their outcome-driven enterprise architecture (EA) practice fuels change, growth, and differentiation. Organizations must also show how their EA practice helps their firm manage risk, drive cost efficiency, improve customer experience, and increase revenue.
Nominations for both award categories are open to organizations with 1,000 or more employees that are using technology to improve business outcomes. Technology leaders — including chief information officers, chief technology officers, chief digital officers, and enterprise architects across North America; Europe, the Middle East, and Africa (EMEA); and Asia Pacific (APAC) — are encouraged to apply.
Additional details on how to apply for Forrester’s 2024 Technology Awards:
- North America. Organizations in North America can visit here, with an awards submission deadline of May 20, 2024. Award recipients will be announced prior to and honored at Forrester’s Technology & Innovation Summit North America, being held in Austin, Texas, and digitally, September 9–12, 2024.
- EMEA. Organizations in EMEA can visit here, with an awards submission deadline of June 20, 2024. Award recipients will be announced prior to and honored at Forrester’s Technology & Innovation Summit EMEA, being held in London and digitally, October 9–11, 2024.
- Asia Pacific. Organizations in APAC can visit here, with an awards submission deadline of July 9, 2024. Award recipients will be announced prior to and honored at Forrester’s Technology & Innovation Summit APAC, being held in Sydney and digitally, October 29, 2024.
“Forrester’s Technology Awards will honor organizations that continually pursue the improvement of business results through technology,” said Laura Koetzle, vice president and group research director at Forrester. “These organizations embody the three guiding principles of high-performance IT strategy: alignment, trust, and adaptivity.”
“Enterprise architecture plays a critical role in driving growth and making a tangible difference in business outcomes. By identifying and describing the future and current state of the enterprise, EA provides one of the most effective ways to realize the organization’s objectives. Recognizing and celebrating EA practices and initiatives around the world has never been more important,” said Steve Nunn, president and CEO of The Open Group.
Resources:
- Learn more about Forrester’s 2024 Technology Awards program.
- Register to attend Forrester’s Technology & Innovation Summits 2024 in North America, EMEA, and APAC.
About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We help leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth. Through Forrester’s proprietary research, consulting, and events, leaders from around the globe are empowered to be bold at work — to navigate change and put their customers at the center of their leadership, strategy, and operations. Our unique insights are grounded in annual surveys of more than 700,000 consumers, business leaders, and technology leaders worldwide; rigorous and objective research methodologies, including Forrester Wave™ evaluations; more than 100 million real-time feedback votes; and the shared wisdom of our clients. To learn more, visit Forrester.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240205913561/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom